Bradford K. Amman - Nov 26, 2024 Form 4 Insider Report for Vivos Therapeutics, Inc. (VVOS)

Role: Chief Financial Officer
Signature: /s/ Bradford K. Amman
Stock symbol: VVOS
Transactions as of: Nov 26, 2024
Transactions value $: $394,767
Form type: 4
Date filed: 11/27/2024, 04:43 PM
Previous filing: Jun 28, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	VVOS	Common Stock						80	Nov 26, 2024	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VVOS	Stock Option (Right to Buy)	Award	$395K	+150K	+482.36%	$2.64	181K	Nov 26, 2024	Common Stock	150K	$2.64	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On September 7, 2024 (the "Grant Date"), the Reporting Person received a grant of 180,533 stock options, which grant was made under but subject to stockholder approval of the Issuer's 2024 Omnibus Equity Incentive Plan and such grant at the Issuer's 2024 Annual Meeting. Such meeting was held, and such stockholder approval was obtained, on November 26, 2024. Stock options shall vest and become exercisable in three installments subject to achievement of the following three performance metrics: (1) quarter over quarter revenue growth of at least 15% over the same prior year quarter, (2) total stockholder return from date of grant, and (3) positive cash flow for two consecutive quarters.

Content

On September 7, 2024 (the "Grant Date"), the Reporting Person received a grant of 180,533 stock options, which grant was made under but subject to stockholder approval of the Issuer's 2024 Omnibus Equity Incentive Plan and such grant at the Issuer's 2024 Annual Meeting. Such meeting was held, and such stockholder approval was obtained, on November 26, 2024. Stock options shall vest and become exercisable in three installments subject to achievement of the following three performance metrics: (1) quarter over quarter revenue growth of at least 15% over the same prior year quarter, (2) total stockholder return from date of grant, and (3) positive cash flow for two consecutive quarters.